Christopher J. Nardo
Senior VP & Chief Development OfficerDr. Christopher J. Nardo, also known as Chris, M.P.H., Ph.D. had been Senior Vice President of Development at Dermata Therapeutics, Inc. since June 2015 until July 01, 2022 and serves as its Senior Vice President and Chief Development Officer since July 01, 2022. Dr. Nardo has experience in the pharmaceutical industry. From September 2010 to May 2015, Dr. Nardo served in positions of increasing responsibility at Allergan, PLC, initially leading clinical development of BOTOX? for the treatment of Over Active Bladder from Phase 3 to product approval and launch and ultimately leading clinical development for the aesthetic group within the Dermatology Therapeutic Area, as well as serving as Global Development Team Leader for the Allergan/Medytox collaboration including serving as the Chair of the AGN/MTX Joint Development Committee. From 2005 to 2010, Dr. Nardo served as Vice President, Clinical Operations and Biostatistics at Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI). Prior to that, Dr. Nardo held various clinical development leadership positions at CancerVax Corporation, The Immune Response Corporation and Procter and Gamble Company. Dr. Nardo obtained a Ph.D. in Epidemiology from the Gillings School of Public Health at the University of North Carolina at Chapel Hill, his M.P.H. in Epidemiology and Biostatistics from the School of Public Health at San Diego State University and his B.S. in Biology at Loyola Marymount University.
公司职务
- 公司名称Dermata Therapeutics, Inc.股票代码DRMA职务Senior VP & Chief Development Officer共事同僚
